NON-SMALL CELL LUNG CANCER MARKET ANALYSIS

Non-Small Cell Lung Cancer Market Size and Trends

Global non-small cell lung cancer market is estimated to be valued at USD 26.10 Bn in 2024 and is expected to reach USD 49.11 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 9.4% from 2024 to 2031.

To learn more about this report, request sample copy

Increasing incidence of lung cancer worldwide due to growing tobacco consumption, rising pollution levels and aging population can drive the non-small cell lung cancer market growth The market growth is driven by increasing research and development activities for novel therapeutics, rising combination therapy and immunotherapy, and growing awareness about early diagnosis and treatment. Moreover, ongoing clinical trials evaluating new drug targets, innovative drug delivery methods and personalized medicine can offer opportunities for non-small cell lung cancer market growth over the forecast period.

Increasing prevalence of non-small cell lung cancer

Increasing prevalence of non-small cell lung cancer (NSCLC) cases can drive the market growth. NSCLC constitutes around 80-85% of all lung cancer cases, and is the leading cause of cancer-related deaths worldwide. According to the data published by World Health Organization (WHO), approximately 2.21 million new lung cancer cases were diagnosed in 2020, making it the second most commonly diagnosed cancer globally. Among these, over 1.8 million cases were NSCLC. The high risk of mortality associated with NSCLC, with a 5-year survival rate of around 18-20%, has led to greater emphasis on early detection and effective treatment options. Advanced diagnostic techniques along with improved understanding of NSCLC at the molecular level has enabled targeted therapies. Pharmaceutical companies have correspondingly ramped up research and development of novel drug formulations over the past decade. Some of the newly approved drug regimens have shown promising efficacy outcomes with fewer side effects in clinical trials. For example, immune checkpoint inhibitors that help enhance the body's immune response against cancer cells has emerged as a major breakthrough. Drugs like Pembrolizumab, Nivolumab and Atezolizumab have notably improved progression-free and overall survival rates in specific patient groups as compared to standard chemotherapy, according to studies  by the American Society of Clinical Oncology.

Aging Population and Improving Diagnosis Rates

With overall enhancements in living standards and healthcare access, populations across the world are progressively aging. While this longevity is a positive outcome of development, it also contributes to higher risks of cancer. Aging is a significant risk factor for cancers like non-small cell lung cancer. The biological changes in cells and immune system with growing age weaken the body's ability to identify and eliminate malignant growths in the lungs. A large section of the current elderly population would have been exposed to unregulated tobacco consumption in the mid-20th century before awareness rose around its risks. This leads to higher incidence of lung cancer as residues of past addiction impacts their health today.